2026 KRAS G12C NSCLC clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

Anbenitamab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Azilsartan Kamedoxomil/Amlodipine Besylate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

2026 EGFR-Mutant NSCLC clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.

Stoke Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Avidity Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Silence Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Wave Life Sciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Dyne Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Crinetics Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Cytokinetics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Scholar Rock 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.